Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 6706691
Immunosupportive drug sparing diet
expired -
US 6706509
Oncoprotein protein kinase
expired -
US 6703050
Methods and compositions for the prevention or treatment of cancer
expired -
US 6703020
Antibody conjugate methods for selectively inhibiting VEGF
expired -
US 6703414
Device and method for treating restenosis
expired -
US 6699482
Leptospira rare outer membrane proteins
expired -
US 6699459
Methods of treating lung inflammation
expired -
US 6696089
Nanogel networks including polyion polymer fragments and biological agent compositions thereof
expired -
US 6696559
Antimicrobial peptides and methods of use
expired -
US 6696585
Functionalized nanoparticles
expired -
US 6696407
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
expired -
US 6696441
Inhibition of p53-induced stress response
expired -
US 6696079
Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes
expired -
US 6693075
Modified vitamin K-dependent polypeptides
expired -
US 6692763
Methods for treating postmenopausal women using ultra-low doses of estrogen
expired -
US 6692759
Methods for preparing and using implantable substance delivery devices
expired -
US 6693130
Inhibitors of epoxide hydrolases for the treatment of hypertension
expired -
US 6692741
Treatment of acute lung injury and fibrosis with antagonists of &bgr;6-specific antibodies
expired -
US 6693183
MURINE &agr; (1,3) FUCOSYLTRANSFERASE FUC-TVII, DNA ENCODING THE SAME, METHOD FOR PREPARING THE SAME, ANTIBODIES RECOGNIZING THE SAME, IMMUNOASSAYS FOR DETECTING THE SAME, PLASMIDS CONTAINING SUCH DNA, AND CELLS CONTAINING SUCH A PLASMID
expired -
US 6692724
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
expired -
US 6689767
Triterpenes having antibacterial activity
expired -
US 6689561
Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
expired -
US 6689775
Uses of thioredoxin
expired -
US 6689575
I&kgr;B kinase, subunits thereof, and methods of using same
expired -
US 6689362
Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal antibody (TXU-7) linked to the pokeweed antiviral protein (PAP)
expired -
US 6689877
Methods and compositions for the treatment of human immunodeficiency virus infection
expired -
US 6689338
Bioconjugates of nanoparticles as radiopharmaceuticals
expired -
US 6689864
Cyclin dependent kinase 4 inhibitor
expired -
US 6689878
Target of RNAIII activating protein (TRAP)
expired -
US 6686445
Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
expired -
US 6686338
Enzyme inhibitors for metabolic redirection
expired -
US 6686334
Use of inhibitors of protein kinase C epsilon to treat pain
expired -
US 6686190
Methods for enhancing the production of viral vaccines in cell culture
expired -
US 6685945
Cloned Leptospira outer membrane protein
expired -
US 6685626
Compositions, devices, methods, and kits for induction of adhesions
expired -
US 6683047
Method of inhibiting transcription utilizing nuclear receptors
expired -
US 6682906
Cloned glutamic acid decarboxylase
expired -
US 6683058
Methods for therapy of neurodegenerative disease of the brain
expired -
US 6683069
Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin
expired -
US 6683059
Mini-E1A gene and gene products
expired -
US 6680171
I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
expired -
US 6680172
Treatments and markers for cancers of the central nervous system
expired -
US 6680331
Lactam and thiolactam derivatives as anesthetic and conscious sedation agents
expired -
US 6680196
Gene that is amplified and overexpressed in cancer and methods of use thereof
expired -
US 6677439
Methods for isolating T. pallidum rare outer membrane proteins
expired -
US 6676943
Human complement C3-degrading protein from Streptococcus pneumoniae
expired -
US 6676941
Antibody conjugate formulations for selectively inhibiting VEGF
expired -
US 6677433
Stabilization of hypoallergenic, hyperdigestible previously reduced proteins
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory